Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
desquaxel
- Development stage
- Preclinical
- Administration
- Injection
01
Overview
Desquaxel is referenced as an injectable drug evaluated in a post-marketing clinical study for second-line treatment of patients with malignant tumors. However, no detailed information about its chemical structure, mechanism of action, or therapeutic class is available from the provided sources. There is no evidence that it corresponds to any well-known pharmaceutical agent such as docetaxel or paclitaxel; nor does it match any established generic or brand name in major drug databases. Its precise pharmacological profile, developer, and approved indications remain unclear based on current public data[2].
- Brand names
- desquaxel
- Other names
- desquaxel
Beyond the preview
Go deeper on desquaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on desquaxel.